PT  - JOURNAL ARTICLE
AU  - Eve M. Taylor
AU  - Deborah A. Otero
AU  - William A. Banks
AU  - John S. O'Brien
TI  - Designing Stable Blood-Brain Barrier-Permeable Prosaptide Peptides for Treatment of Central Nervous System Neurodegeneration
DP  - 2000 May 01
TA  - Journal of Pharmacology and Experimental Therapeutics
PG  - 403--409
VI  - 293
IP  - 2
4099  - http://jpet.aspetjournals.org/content/293/2/403.short
4100  - http://jpet.aspetjournals.org/content/293/2/403.full
SO  - J Pharmacol Exp Ther2000 May 01; 293
AB  - Prosaposin-derived peptides have been proposed as potential therapeutics for neurodegenerative diseases. Previously, we reported that the minimal length for bioactivity was 12 amino acids, and key amino acids were described based on interspecies conservation. In this article, we have further investigated the sequence requirements for bioactive Prosaptide (trademark of Myelos Corporation) peptides in terms of length and amino acid identity. The use of Prosaptide peptides for treatment of central nervous system (CNS) disorders requires that they are stable in vivo. Although robust effects of our prototypical peptide Prosaptide TX14(A) have been shown in the peripheral nervous system, minimal success has been achieved when treating the CNS in rats and this may be due to instability of Prosaptide TX14(A) in brain. Herein, we demonstrate that, indeed, Prosaptide TX14(A) is rapidly degraded in the brain and we have attempted to design prosaptides with increased CNS stability. One peptide, Prosaptide TX15-2, shows increased stability in brain and may be of use in the treatment of CNS disorders. With the aim of designing Prosaptide peptides that may be systemically administered for CNS treatment, we have investigated the blood-brain barrier permeability of Prosaptide TX14(A) and TX15-2. Both of these peptides cross the blood-brain barrier via a nonspecific mechanism. The American Society for Pharmacology and Experimental Therapeutics